Arrowhead clarifies its HBV patent situation

Arrowhead Research (ARWR -9.7%) says it is unencumbered in its efforts to develop its HBV drug candidate ARC-520. It has broad access to the IP necessary to develop the product and has no restrictions on its freedom to operate. The company signed a license agreement with Alnylam (ALNY) in January 2012 for HBV-related IP plus it owns other patents related to the drug's technology.  It believes that ARC-520 does not infringe on any patents in Alnylam's McSwiggen patent estate.

ARWR shares took it on the chin today due to the market's perception that ALNY's HBV patents may be a issue for ARWR.

From other sites
Comments (3)
  • Patent News
    , contributor
    Comments (1474) | Send Message
    looks like they are obfuscating and there will be blood.
    15 Jun 2014, 08:00 AM Reply Like
  • wyattkap
    , contributor
    Comments (43) | Send Message
    Manipulated negative comments by people not worthy. I bought MORE as nothing but GREAT NEWS coming over the next several months. My money is where my mouth is.
    15 Jun 2014, 08:03 PM Reply Like
  • kostas3010
    , contributor
    Comment (1) | Send Message
    Pisses me off that it took so long for someone to come out with any commentary as to why ARWR was down 15% on Friday. I had no choice but to take a loss at $11.40.


    I hate how this market is so manipulated! These market makers and high frequency traders should be shot!!
    15 Jun 2014, 10:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs